CJC-1295 and Ipamorelin: What FDA Recorded

CJC-1295 and ipamorelin are sold together, usually as a “stack”, on the theory that one extends a growth hormone pulse while the other triggers it. Both are flagged in FDA’s compounding safety records, and one of them carries language FDA did not use for any other peptide in this market: “serious adverse events… including increased heart rate and systemic vasodilatory reaction.”^[1]

Neither is approved for anything. Neither has been tested for weight loss. What human trial data exists measured hormone levels, or treated an entirely unrelated condition.

Where each one actually sits

“FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”^[1]

— FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

The theory behind stacking them

The two act on different receptors, which is the whole argument for combining them. CJC-1295 is a growth hormone-releasing hormone analog engineered for a long half-life. Ipamorelin is a ghrelin mimetic — described in the literature as the first selective growth hormone secretagogue, meaning it raises GH without the cortisol and prolactin rises that made earlier compounds in its class unattractive.^[2]

That pharmacology is real. CJC-1295 does produce prolonged elevation of growth hormone and IGF-I in humans — that is exactly what the 2006 trial measured.^[3] The gap is what comes next: raising a hormone is not the same as producing a clinical result, and the second step has not been tested.

What the human trials actually studied

• CJC-1295, 2006 — prolonged stimulation of GH and IGF-I secretion in humans. An endocrine measurement study, not a weight or body-composition trial.^[3]
• Ipamorelin, 1998 — the original characterization paper establishing it as a selective GH secretagogue.^[2]
• Ipamorelin, 1999 — pharmacokinetic and pharmacodynamic modeling in human volunteers.^[4]
• Ipamorelin, 2014 — a randomized, controlled proof-of-concept study for the management of postoperative ileus, a bowel-motility problem after surgery.^[5] Nothing to do with weight.

Against what the sellers list beside it

On the same menu you will typically find compounded semaglutide or tirzepatide. Those molecules have phase 3 trials with thousands of participants and body weight as the primary endpoint. This pair has hormone-level studies and an ileus trial.

That is not an argument that growth hormone does nothing — it demonstrably affects body composition in people who are deficient in it. It is an argument about what has been demonstrated in people who are not. The same gap runs through sermorelin, which has a genuine approval history and no weight-loss trial either.

If you are being offered the stack

1. Ask about the cardiovascular effects by name. FDA identified increased heart rate and systemic vasodilatory reaction with CJC-1295. A seller offering it should be able to discuss that rather than hear it from you.
2. Ask which pharmacy compounds it and under what authority, given that ipamorelin is in active category 2 for 503B and CJC-1295 is on neither list.
3. Ask for the weight-loss trial. Not a mechanism, not a case series — the trial. Notice what arrives instead.
4. Ask what it adds to the GLP-1 you are already paying for, and what that addition costs per month.

Common questions